BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, D'amico F, Ciarleglio FA, Boccagni P, Brolese A, Zanus G, D'amico DF. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? Journal of Hepatology 2004;40:124-31. [DOI: 10.1016/j.jhep.2003.09.027] [Cited by in Crossref: 133] [Cited by in F6Publishing: 121] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2006;22:248-53. [DOI: 10.1097/01.mog.0000218961.86182.8c] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 5.1] [Reference Citation Analysis]
2 Waly Raphael S, Yangde Z, Yuxiang C. Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol 2012;2012:421673. [PMID: 22655206 DOI: 10.5402/2012/421673] [Cited by in Crossref: 25] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
3 Maida M, Orlando E, Cammà C, Cabibbo G. Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol. 2014;20:4141-4150. [PMID: 24764652 DOI: 10.3748/wjg.v20.i15.4141] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 55] [Article Influence: 9.8] [Reference Citation Analysis]
4 Miller G, Schwartz LH, D'Angelica M. The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surg Oncol Clin N Am. 2007;16:343-368. [PMID: 17560517 DOI: 10.1016/j.soc.2007.04.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
5 Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Interventional therapies for hepatocellular carcinoma. Cancer Imaging 2012;12:79-88. [PMID: 22487698 DOI: 10.1102/1470-7330.2012.0011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
6 Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005;54:411-8. [PMID: 15710992 DOI: 10.1136/gut.2004.048124] [Cited by in Crossref: 173] [Cited by in F6Publishing: 158] [Article Influence: 10.8] [Reference Citation Analysis]
7 Rim CH, Seong J. Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiat Oncol J. 2016;34:160-167. [PMID: 27730805 DOI: 10.3857/roj.2016.01970] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
8 Ribeiro de Souza A, Reig M, Bruix J. Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. Expert Opinion on Pharmacotherapy 2016;17:1923-36. [DOI: 10.1080/14656566.2016.1225722] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
9 Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, Beneduce G, Castello G, De Rosa V, Petrillo A, Ascierto PA, Curley SA, Izzo F. Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma. JCO 2010;28:2220-6. [DOI: 10.1200/jco.2009.26.7765] [Cited by in Crossref: 126] [Cited by in F6Publishing: 67] [Article Influence: 11.5] [Reference Citation Analysis]
10 Huo TI, Huang YH, Lin HC, Wu JC, Chiang JH, Lee PC, Chang FY, Lee SD. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol. 2006;101:975-982. [PMID: 16573785 DOI: 10.1111/j.1572-0241.2006.00462.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
11 Roessler S, Budhu A, Wang XW. Future of molecular profiling of human hepatocellular carcinoma. Future Oncol. 2007;3:429-439. [PMID: 17661718 DOI: 10.2217/14796694.3.4.429] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
12 Cillo U, Vitale A, Grigoletto F, Gringeri E, D’Amico F, Valmasoni M, Brolese A, Zanus G, Srsen N, Carraro A. Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. Am J Transplant. 2007;7:972-981. [PMID: 17391137 DOI: 10.1111/j.1600-6143.2006.01719.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 6.5] [Reference Citation Analysis]
13 Sorrentino P, D’Angelo S, Tarantino L, Ferbo U, Bracigliano A, Vecchione R. Contrast-enhanced sonography versus biopsy for the differential diagnosis of thrombosis in hepatocellular carcinoma patients. World J Gastroenterol. 2009;15:2245-2251. [PMID: 19437565 DOI: 10.3748/wjg.15.2245] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
14 Huo TI, Hsia CY, Huang YH, Lin HC, Lee PC, Lui WY, Chiang JH, Chiou YY, Loong CC, Lee SD. Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the model for end-stage liver disease (MELD), MELD-sodium, and five cancer staging systems. J Clin Gastroenterol. 2009;43:773-781. [PMID: 19262404 DOI: 10.1097/mcg.0b013e31818dd962] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
15 Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7:35-41. [PMID: 18333159 DOI: 10.1080/13651820410024058] [Cited by in Crossref: 153] [Cited by in F6Publishing: 134] [Article Influence: 13.9] [Reference Citation Analysis]
16 Kulik LM. Advancements in hepatocellular carcinoma: . Current Opinion in Gastroenterology 2007;23:268-74. [DOI: 10.1097/mog.0b013e3280ec5113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Cammà C, Di Marco V, Cabibbo G, Latteri F, Sandonato L, Parisi P, Enea M, Attanasio M, Galia M, Alessi N, Licata A, Latteri MA, Craxì A. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008;28:62-75. [PMID: 18373636 DOI: 10.1111/j.1365-2036.2008.03692.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 4.0] [Reference Citation Analysis]
18 Shih Y, Yen AM, Yen D, Hung L, Chen H, Liou H. A Novel Postoperative Seizure Classification for Long-term Mortality of Patients With Intractable Epilepsy: Comparison With the Engel System. Neurosurgery 2011;69:64-71. [DOI: 10.1227/neu.0b013e3182134126] [Cited by in Crossref: 6] [Article Influence: 0.6] [Reference Citation Analysis]
19 Vitale A, Saracino E, Boccagni P, Brolese A, D'amico F, Gringeri E, Neri D, Srsen N, Valmasoni M, Zanus G, Carraro A, Violi P, Pauletto A, Bassi D, Polacco M, Burra P, Farinati F, Feltracco P, Romano A, D'amico D, Cillo U. Validation of the BCLC Prognostic System in Surgical Hepatocellular Cancer Patients. Transplantation Proceedings 2009;41:1260-3. [DOI: 10.1016/j.transproceed.2009.03.054] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
20 Lee JH, Kim HY, Kim YJ, Yoon JH, Chung JW, Lee HS. Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area. J Gastroenterol Hepatol. 2015;30:696-705. [PMID: 25250761 DOI: 10.1111/jgh.12788] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
21 Kudo M. International comparison of treatment outcomes based on staging systems. Hepatol Res 2007;37 Suppl 2:S216-22. [PMID: 17877486 DOI: 10.1111/j.1872-034X.2007.00188.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
22 Seong J, Shim SJ, Lee IJ, Han KH, Chon CY, Ahn SH. Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:1037-42. [PMID: 17234356 DOI: 10.1016/j.ijrobp.2006.10.035] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
23 Huo T, Lin H, Huang Y, Wu J, Chiang J, Lee P, Lee S. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer 2006;107:141-8. [DOI: 10.1002/cncr.21972] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
24 Yang D, Wu H, Nong W, Zheng M, Li A, Wang Y, Li M, Chen Q, Yuan S, Yu J, Liao W. A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2021;45:101509. [PMID: 33744828 DOI: 10.1016/j.clinre.2020.07.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Vogeler M, Mohr I, Pfeiffenberger J, Sprengel SD, Klauss M, Teufel A, Chang DH, Springfeld C, Longerich T, Merle U, Mehrabi A, Weiss KH, Mieth M. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. J Cancer Res Clin Oncol 2020;146:1033-50. [PMID: 32107625 DOI: 10.1007/s00432-020-03135-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
26 Kim YK, Kim CS, Chung GH, Han YM, Lee SY, Jin GY, Lee JM. Radiofrequency ablation of hepatocellular carcinoma in patients with decompensated cirrhosis: evaluation of therapeutic efficacy and safety. AJR Am J Roentgenol 2006;186:S261-8. [PMID: 16632686 DOI: 10.2214/AJR.04.1266] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
27 Guglielmi A, Ruzzenente A, Pachera S, Valdegamberi A, Sandri M, D’Onofrio M, Iacono C. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol. 2008;103:597-604. [PMID: 17970836 DOI: 10.1111/j.1572-0241.2007.01604.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 5.0] [Reference Citation Analysis]
28 Gan W, Huang JL, Zhang MX, Fu YP, Yi Y, Jing CY, Fan J, Zhou J, Qiu SJ. New nomogram predicts the recurrence of hepatocellular carcinoma in patients with negative preoperative serum AFP subjected to curative resection. J Surg Oncol 2018;117:1540-7. [PMID: 29572833 DOI: 10.1002/jso.25046] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
29 Chen T, Chang T, Huang P, Tsai M, Lin L, Liu C, Ho K, Siauw C, Chao P, Tung J. Management and patient survival in hepatocellular carcinoma: Does the physician's level of experience matter? Journal of Gastroenterology and Hepatology 2008;23:e179-88. [DOI: 10.1111/j.1440-1746.2008.05341.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
30 Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One 2014;9:e90929. [PMID: 24603710 DOI: 10.1371/journal.pone.0090929] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
31 Vitale A, Farinati F, Finotti M, Di Renzo C, Brancaccio G, Piscaglia F, Cabibbo G, Caturelli E, Missale G, Marra F, Sacco R, Giannini EG, Trevisani F, Cillo U, Associazione Italiana Per Lo Studio Del Fegato Aisf Hcc Special Interest Group, Italian Liver Cancer Ita Li Ca Study Group. Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. Cancers (Basel) 2021;13:1673. [PMID: 33918125 DOI: 10.3390/cancers13071673] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Zanetto A, Shalaby S, Vitale A, Mescoli C, Ferrarese A, Gambato M, Franceschet E, Germani G, Senzolo M, Romano A, Angeli P, Rugge M, Farinati F, Forton DM, Cillo U, Burra P, Russo FP. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. Liver Transpl. 2017;23:1103-1112. [PMID: 28544587 DOI: 10.1002/lt.24790] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 11.3] [Reference Citation Analysis]
33 Ziogas IA, Tsoulfas G. Advances and challenges in laparoscopic surgery in the management of hepatocellular carcinoma. World J Gastrointest Surg 2017;9:233-45. [PMID: 29359029 DOI: 10.4240/wjgs.v9.i12.233] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
34 Naar L, Hatzaras I. Liver Resection for Hepatocellular Carcinoma and the Barcelona Clinic Liver Cancer Criteria: Is It Time to Push the Limits? Ann Surg Oncol 2020;27:2122-4. [PMID: 32297086 DOI: 10.1245/s10434-020-08459-w] [Reference Citation Analysis]
35 Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:667-685. [PMID: 20633193 DOI: 10.1111/j.1872-034x.2010.00673.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 45] [Article Influence: 12.9] [Reference Citation Analysis]
36 Wei S, Hao X, Zhan D, Xiong M, Li K, Chen X, Huang Z. Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified? J Huazhong Univ Sci Technolog Med Sci. 2011;31:637-641. [PMID: 22038353 DOI: 10.1007/s11596-011-0574-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
37 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1696] [Article Influence: 707.3] [Reference Citation Analysis]
38 Ding HF, Zhang XF, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Lv Y, Pawlik TM. Prediction of tumor recurrence by α-fetoprotein model after curative resection for hepatocellular carcinoma. Eur J Surg Oncol 2021;47:660-6. [PMID: 33082065 DOI: 10.1016/j.ejso.2020.10.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
39 Chen CH, Hu FC, Huang GT, Lee PH, Tsang YM, Cheng AL, Chen DS, Wang JD, Sheu JC. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients. Eur J Cancer. 2009;45:1630-1639. [PMID: 19157858 DOI: 10.1016/j.ejca.2008.12.025] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 4.7] [Reference Citation Analysis]
40 Vilana R, Forner A, García Á, Ayuso C, Bru C. Carcinoma hepatocelular: diagnóstico, estadificación y estrategia terapéutica. Radiología 2010;52:385-98. [DOI: 10.1016/j.rx.2010.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
41 Yoneyama K, Taniguchi H, Kiuchi Y, Shibata M, Mitamura K. Prognostic index of liver cirrhosis with ascites with and without hepatocellular carcinoma. Scandinavian Journal of Gastroenterology 2009;39:1272-9. [DOI: 10.1080/00365520410008042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
42 Tannus RK, Almeida-Carvalho SR, Loureiro-Matos CA, Miziara-Gonzalez A, Salzedas-Netto AA, Szejnfeld D, D'Ippolito G, Pereira-Lanzoni V, Souza-Silva I. Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems. PLoS One 2018;13:e0194922. [PMID: 29617435 DOI: 10.1371/journal.pone.0194922] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
43 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
44 Shah SA, Tan JC, McGilvray ID, Cattral MS, Levy GA, Greig PD, Grant DR. Does microvascular invasion affect outcomes after liver transplantation for HCC? A histopathological analysis of 155 consecutive explants. J Gastrointest Surg 2007;11:464-71. [PMID: 17436131 DOI: 10.1007/s11605-006-0033-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
45 Vitale A, Navaglia F, Ramírez Morales R, Frigo AC, Basso D, D’Amico F, Zanus G, Bonsignore P, Farinati F, Burra P. Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies. PLoS One. 2011;6:e23093. [PMID: 21912636 DOI: 10.1371/journal.pone.0023093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
46 Goodman ZD, Terracciano LM, Wee A. Tumours and tumour-like lesions of the liver. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 761-851. [DOI: 10.1016/b978-0-7020-3398-8.00014-3] [Cited by in Crossref: 21] [Article Influence: 2.3] [Reference Citation Analysis]
47 Clark T, Maximin S, Meier J, Pokharel S, Bhargava P. Hepatocellular Carcinoma: Review of Epidemiology, Screening, Imaging Diagnosis, Response Assessment, and Treatment. Curr Probl Diagn Radiol. 2015;44:479-486. [PMID: 25979220 DOI: 10.1067/j.cpradiol.2015.04.004] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 13.3] [Reference Citation Analysis]
48 Li H, Huang W, Luo R. The microRNA-325 inhibits hepatocellular carcinoma progression by targeting high mobility group box 1. Diagn Pathol 2015;10:117. [PMID: 26194496 DOI: 10.1186/s13000-015-0323-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
49 Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D'amico F, Ciarleglio FA, Bridda A, Francesco D'amico D. Prospective validation of the Barcelona Clinic Liver Cancer staging system. Journal of Hepatology 2006;44:723-31. [DOI: 10.1016/j.jhep.2005.12.015] [Cited by in Crossref: 275] [Cited by in F6Publishing: 247] [Article Influence: 18.3] [Reference Citation Analysis]
50 Barone C, Koeberle D, Metselaar H, Parisi G, Sansonno D, Spinzi G. Multidisciplinary approach for HCC patients: hepatology for the oncologists. Ann Oncol. 2013;24 Suppl 2:ii15-ii23. [PMID: 23715939 DOI: 10.1093/annonc/mdt053] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
51 Lee S, Kim BK, Song K, Park JY, Ahn SH, Kim SU, Han KH, Kim DY; Korea Central Cancer Registry. Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database. J Gastroenterol Hepatol. 2016;31:842-847. [PMID: 26513311 DOI: 10.1111/jgh.13218] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
52 Ziada DH, El Sadany S, Soliman H, Abd-Elsalam S, Salama M, Hawash N, Selim A, Hamisa M, Elsabagh HM. Prevalence of hepatocellular carcinoma in chronic hepatitis C patients in Mid Delta, Egypt: A single center study. J Egypt Natl Canc Inst 2016;28:257-62. [PMID: 27378258 DOI: 10.1016/j.jnci.2016.06.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
53 Tateishi R, Yoshida H, Shiina S, Imamura H, Hasegawa K, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Makuuchi M, Omata M. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut. 2005;54:419-425. [PMID: 15710994 DOI: 10.1136/gut.2003.035055] [Cited by in Crossref: 174] [Cited by in F6Publishing: 156] [Article Influence: 10.9] [Reference Citation Analysis]
54 Cillo U, Vitale A, Brolese A, Zanus G, Neri D, Valmasoni M, Bonsignore P, Grigoletto F, Burra P, Farinati F, D'amico DF. Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma. J Surg Oncol 2007;95:213-20. [DOI: 10.1002/jso.20641] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
55 Qiao G, Cucchetti A, Li J, Cescon M, Ercolani G, Liu G, Pinna AD, Li L, Shen F, Ren J. Applying of pretreatment extent of disease system in patients with hepatocellular carcinoma after curative partial hepatectomy. Oncotarget 2016;7:30408-19. [PMID: 27007152 DOI: 10.18632/oncotarget.8149] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
56 Vauthey J, Ribero D, Abdalla EK, Jonas S, Bharat A, Schumacher G, Lerut J, Chapman WC, Hemming AW, Neuhaus P. Outcomes of Liver Transplantation in 490 Patients with Hepatocellular Carcinoma: Validation of a Uniform Staging after Surgical Treatment. Journal of the American College of Surgeons 2007;204:1016-27. [DOI: 10.1016/j.jamcollsurg.2006.12.043] [Cited by in Crossref: 61] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
57 Bae SH, Kim MS, Cho CK, Kim KB, Lee DH, Han CJ, Park SC, Kim YH. Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma. J Korean Med Sci. 2013;28:213-219. [PMID: 23400333 DOI: 10.3346/jkms.2013.28.2.213] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
58 Chu KK, Cheung TT. Update in management of hepatocellular carcinoma in Eastern population. World J Hepatol. 2015;7:1562-1571. [PMID: 26085915 DOI: 10.4254/wjh.v7.i11.1562] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
59 Jaruvongvanich V, Sempokuya T, Wong L. Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma? J Gastrointest Oncol 2018;9:750-61. [PMID: 30151272 DOI: 10.21037/jgo.2018.05.11] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
60 Park S, Yoon WS, Rim CH. Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints. World J Gastroenterol 2020;26:393-403. [PMID: 32063688 DOI: 10.3748/wjg.v26.i4.393] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
61 Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T, Matsunaga T. Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol. 2008;23:445-452. [PMID: 17683486 DOI: 10.1111/j.1440-1746.2007.05075.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
62 Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T. Review of current staging systems for hepatocellular carcinoma. Hepatology Research 2007;37:S210-5. [DOI: 10.1111/j.1872-034x.2007.00187.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
63 Ridruejo E, Mandó OG, Dávalos M, Díaz C, Vilches A. Hepatocellular carcinoma in renal transplant patients. Transplant Proc. 2005;37:2086-2088. [PMID: 15964346 DOI: 10.1016/j.transproceed.2005.03.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
64 Tellapuri S, Sutphin PD, Beg MS, Singal AG, Kalva SP. Staging systems of hepatocellular carcinoma: A review. Indian J Gastroenterol 2018;37:481-91. [DOI: 10.1007/s12664-018-0915-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
65 Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL, Abou-Alfa GK. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol. 2010;28:2889-2895. [PMID: 20458042 DOI: 10.1200/jco.2009.25.9895] [Cited by in Crossref: 186] [Cited by in F6Publishing: 118] [Article Influence: 16.9] [Reference Citation Analysis]
66 Cillo U, Vitale A, Navaglia F, Basso D, Montin U, Bassanello M, D'Amico F, Ciarleglio FA, Brolese A, Zanus G, De Pascale V, Plebani M, D'Amico DF. Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. World J Gastroenterol 2005;11:6920-5. [PMID: 16437593 DOI: 10.3748/wjg.v11.i44.6920] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
67 Kaseb AO, Abaza YM, Roses RE. Multidisciplinary management of hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:247-259. [PMID: 22941025 DOI: 10.1007/978-3-642-16037-0_16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
68 Marrero JA, Kudo M, Bronowicki JP. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist. 2010;15 Suppl 4:23-33. [PMID: 21115578 DOI: 10.1634/theoncologist.2010-s4-23] [Cited by in Crossref: 79] [Cited by in F6Publishing: 43] [Article Influence: 7.9] [Reference Citation Analysis]
69 Ha Y, Shim JH, Kim SO, Kim KM, Lim YS, Lee HC. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. J Gastroenterol Hepatol. 2014;29:787-793. [PMID: 24224567 DOI: 10.1111/jgh.12452] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
70 Pascual S, Zapater P, Such J, Garcia-herola A, Sempere L, Irurzun J, Palazon JM, Carnicer F, Perez-mateo M. Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver Int 2006;26:673-9. [DOI: 10.1111/j.1478-3231.2006.01282.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
71 Lefkowitch JH. Neoplasms and Nodules. Scheuer's Liver Biopsy Interpretation. Elsevier; 2010. pp. 181-231. [DOI: 10.1016/b978-0-7020-3410-7.00017-4] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
72 Vande Lune P, Abdel Aal AK, Klimkowski S, Zarzour JG, Gunn AJ. Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization. J Clin Transl Hepatol 2018;6:175-88. [PMID: 29951363 DOI: 10.14218/JCTH.2017.00045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
73 Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX, Wang XW. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70:10202-10212. [PMID: 21159642 DOI: 10.1158/0008-5472.can-10-2607] [Cited by in Crossref: 478] [Cited by in F6Publishing: 355] [Article Influence: 47.8] [Reference Citation Analysis]
74 Cho YK, Chung JW, Kim JK, Ahn YS, Kim MY, Park YO, Kim WT, Byun JH. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer. 2008;112:352-361. [PMID: 18008352 DOI: 10.1002/cncr.23185] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 6.4] [Reference Citation Analysis]
75 Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146: 1691-700. e3. [PMID: 24583061 DOI: 10.1053/j.gastro.2014.02.032] [Cited by in Crossref: 339] [Cited by in F6Publishing: 307] [Article Influence: 48.4] [Reference Citation Analysis]
76 Zhu Q, Li N, Zeng X, Han Q, Li F, Yang C, Lv Y, Zhou Z, Liu Z. Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. Oncotarget. 2015;6:4440-4450. [PMID: 25686836 DOI: 10.18632/oncotarget.2913] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
77 Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, Tang ZY, Wang XW. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology. 2008;47:897-907. [PMID: 18176954 DOI: 10.1002/hep.22160] [Cited by in Crossref: 513] [Cited by in F6Publishing: 478] [Article Influence: 39.5] [Reference Citation Analysis]
78 Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol. 2015;7:406-424. [PMID: 25848467 DOI: 10.4254/wjh.v7.i3.406] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
79 Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist. 2010;15 Suppl 4:42-52. [PMID: 21115580 DOI: 10.1634/theoncologist.2010-s4-42] [Cited by in Crossref: 102] [Cited by in F6Publishing: 59] [Article Influence: 10.2] [Reference Citation Analysis]
80 Schwartz M, D'amico F, Vitale A, Emre S, Cillo U. Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid? European Journal of Surgical Oncology (EJSO) 2008;34:256-62. [DOI: 10.1016/j.ejso.2007.07.208] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
81 Kang HY, Shin HD, Kim SB, Song IH. Prognosis predictability of hepatocellular carcinoma according to staging systems in hepatitis B virus-endemic area. Clin Res Hepatol Gastroenterol 2012;36:357-64. [PMID: 22326248 DOI: 10.1016/j.clinre.2011.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
82 Kung J, Macdougall M, Madhavan K, Garden O, Parks R. Predicting survival in patients with hepatocellular carcinoma: A UK perspective. European Journal of Surgical Oncology (EJSO) 2007;33:188-94. [DOI: 10.1016/j.ejso.2006.10.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
83 Gomaa AI, Al-Khatib A, Abdel-Razek W, Hashim MS, Waked I. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging. World J Gastroenterol 2015;21:5654-62. [PMID: 25987792 DOI: 10.3748/wjg.v21.i18.5654] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
84 Huo TI, Huang YH, Lee SD, Wu JC. Is there an ideal prognostic model for hepatocellular carcinoma? Gut 2005;54:1348. [PMID: 16099811 DOI: 10.1136/gut.2005.069468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
85 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
86 Marrero JA. Staging systems for hepatocellular carcinoma: should we all use the BCLC system? J Hepatol. 2006;44:630-632. [PMID: 16503077 DOI: 10.1016/j.jhep.2006.02.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
87 Asmis T, Balaa F, Scully L, Papadatos D, Marginean C, Fasih N, Shaw-Stiffel T, Goel R. Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. Curr Oncol 2010;17:6-12. [PMID: 20404972 DOI: 10.3747/co.v17i2.555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
88 Kovac JD, Ivanovic A, Milovanovic T, Micev M, Alessandrino F, Gore RM. An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation. Radiol Oncol 2021;55:130-43. [PMID: 33544992 DOI: 10.2478/raon-2021-0004] [Reference Citation Analysis]
89 Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430-3446. [PMID: 27622302 DOI: 10.1002/cncr.30237] [Cited by in Crossref: 106] [Cited by in F6Publishing: 102] [Article Influence: 21.2] [Reference Citation Analysis]
90 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
91 Farinati F, Sergio A, Baldan A, Giacomin A, Di Nolfo MA, Del Poggio P, Benvegnu L, Rapaccini G, Zoli M, Borzio F. Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer. 2009;9:33. [PMID: 19171074 DOI: 10.1186/1471-2407-9-33] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 4.6] [Reference Citation Analysis]
92 Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, Imamura H, Sugawara Y, Kokudo N, Makuuchi M. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134:1908-1916. [PMID: 18549877 DOI: 10.1053/j.gastro.2008.02.091] [Cited by in Crossref: 435] [Cited by in F6Publishing: 419] [Article Influence: 33.5] [Reference Citation Analysis]
93 Huang Y, Chen C, Chang T, Chen S, Wang S, Lee H, Lin P, Huang G, Sheu J, Tsai H, Lee P, Chau G, Lui W, Lee S, Wu J. Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery. J Gastroenterol Hepatol 2005;20:765-71. [DOI: 10.1111/j.1440-1746.2005.03746.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
94 Trinchet J, Beaugrand M. Is there an ideal prognostic classification for hepatocellular carcinoma? The quest for the Holy Grail. Journal of Hepatology 2010;53:23-4. [DOI: 10.1016/j.jhep.2010.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
95 Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review: Review of International HCC Guidelines. Cancer 2014;120:2824-38. [DOI: 10.1002/cncr.28730] [Cited by in Crossref: 153] [Cited by in F6Publishing: 145] [Article Influence: 21.9] [Reference Citation Analysis]
96 Jianyong L, Jinjing Z, Lunan Y, Jingqiang Z, Wentao W, Yong Z, Bo L, Tianfu W, Jiaying Y. Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma. Sci Rep 2017;7:41624. [PMID: 28155861 DOI: 10.1038/srep41624] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
97 Yang T, Zhang J, Lu JH, Yang LQ, Yang GS, Wu MC, Yu WF. A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort. J Cancer Res Clin Oncol. 2011;137:739-750. [PMID: 20607551 DOI: 10.1007/s00432-010-0935-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
98 Frenette C, Gish RG. Hepatocellular carcinoma: molecular and genomic guideline for the clinician. Clin Liver Dis 2011;15:307-21, vii-x. [PMID: 21689615 DOI: 10.1016/j.cld.2011.03.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
99 Hafeez Bhatti AB, Dar FS, Waheed A, Shafique K, Sultan F, Shah NH. Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective. Gastroenterol Res Pract 2016;2016:5942306. [PMID: 26955390 DOI: 10.1155/2016/5942306] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
100 Jung YK, Jung CH, Seo YS, Kim JH, Kim TH, Yoo YJ, Kang SH, Yim SY, Suh SJ, An H, Yim HJ, Yeon JE, Byun KS, Um SH. BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. J Gastroenterol Hepatol 2016;31:467-74. [PMID: 26332049 DOI: 10.1111/jgh.13152] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
101 Huo T, Lin H, Hsia C, Wu J, Lee P, Chi C, Lee S. The Model for End-Stage Liver Disease Based Cancer Staging Systems Are Better Prognostic Models for Hepatocellular Carcinoma: A Prospective Sequential Survey. Am J Gastroenterology 2007;102:1920-30. [DOI: 10.1111/j.1572-0241.2007.01370.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
102 Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707-716. [PMID: 15795889 DOI: 10.1002/hep.20636] [Cited by in Crossref: 443] [Cited by in F6Publishing: 394] [Article Influence: 27.7] [Reference Citation Analysis]
103 Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502-510. [PMID: 19141028 DOI: 10.1111/j.1478-3231.2008.01957.x] [Cited by in Crossref: 199] [Cited by in F6Publishing: 190] [Article Influence: 15.3] [Reference Citation Analysis]
104 Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, Milicevic M. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol. 2015;7:2274-2291. [PMID: 26380652 DOI: 10.4254/wjh.v7.i20.2274] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
105 Choi W, Yu SJ, Ahn H, Cho H, Cho YY, Lee M, Yoo J, Cho Y, Lee DH, Cho EJ, Lee J, Kim YJ, Yoon J. A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma? Digestive and Liver Disease 2017;49:1273-9. [DOI: 10.1016/j.dld.2017.07.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Li JW, Goh BG, Chang PE, Tan CK. Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective. World J Gastroenterol. 2017;23:4054-4063. [PMID: 28652658 DOI: 10.3748/wjg.v23.i22.4054] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
107 Endo M, Nishikawa H, Kita R, Kimura T, Ohara Y, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Osaki Y. Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience. Mol Clin Oncol 2016;4:515-22. [PMID: 27073653 DOI: 10.3892/mco.2016.755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
108 Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33:532-540. [PMID: 19847482 DOI: 10.1007/s00270-009-9728-y] [Cited by in Crossref: 92] [Cited by in F6Publishing: 66] [Article Influence: 7.7] [Reference Citation Analysis]
109 Collette S, Bonnetain F, Paoletti X, Doffoel M, Bouché O, Raoul J, Rougier P, Masskouri F, Bedenne L, Barbare J. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Annals of Oncology 2008;19:1117-26. [DOI: 10.1093/annonc/mdn030] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 4.3] [Reference Citation Analysis]
110 Ramos E, Lladó L, Serrano T, Figueras A, Lastra R, Torras J, Figueras J, Rafecas A, Fabregat J. Utility of Cell-cycle Modulators to Predict Vascular Invasion and Recurrence After Surgical Treatment of Hepatocellular Carcinoma. Transplantation 2006;82:753-8. [DOI: 10.1097/01.tp.0000234718.40266.75] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
111 Sirivatanauksorn Y, Tovikkai C. Comparison of staging systems of hepatocellular carcinoma. HPB Surg. 2011;2011:818217. [PMID: 21760664 DOI: 10.1155/2011/818217] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
112 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Reference Citation Analysis]
113 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 235] [Article Influence: 35.3] [Reference Citation Analysis]
114 Huo TI, Huang YH. Staging for hepatocellular carcinoma: treatment strategy matters. Hepatology 2005;41:678; author reply 678-9. [PMID: 15723331 DOI: 10.1002/hep.20583] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
115 Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World J Gastroenterol 2014;20:745-54. [PMID: 24574748 DOI: 10.3748/wjg.v20.i3.745] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
116 Vitale A, D’Amico F, Frigo AC, Grigoletto F, Brolese A, Zanus G, Neri D, Carraro A, D’Amico FE, Burra P. Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg Oncol. 2010;17:2290-2302. [PMID: 20217249 DOI: 10.1245/s10434-010-0993-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
117 Olthoff KM, Forner A, Hübscher S, Fung J. What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation? Liver Transpl. 2011;17 Suppl 2:S26-S33. [PMID: 21656653 DOI: 10.1002/lt.22352] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
118 Davis CR. Interventional radiological treatment of hepatocellular carcinoma. Cancer Control 2010;17:87-99. [PMID: 20404792 DOI: 10.1177/107327481001700204] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
119 Huo T, Wu J, Lee S. Comparison of staging systems for HCC: One more positive answer or mission impossible? Hepatology 2005;42:238-9. [DOI: 10.1002/hep.20758] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
120 Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ishikawa T, Itobayashi E, Shimada N, Takaguchi K, Takizawa D. Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study. Hepatol Res. 2015;Aug 29; Epub ahead of print. [PMID: 26331402 DOI: 10.1111/hepr.12583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
121 Yegin EG, Siykhymbayev A, Eren F, Bekiroglu N, Ozdogan OC. Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging. Annals of Hepatology 2013;12:915-25. [DOI: 10.1016/s1665-2681(19)31297-9] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]